Advice

following a full submission considered under the orphan equivalent process:

pembrolizumab (Keytruda®) is accepted for use within NHSScotland.

Indication under review: As monotherapy for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.

Recurrence-free survival was significantly longer in the pembrolizumab group compared with placebo in a phase III study of adult patients with completely resected, stage III melanoma with lymph node involvement.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of pembrolizumab. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2144
Indication:
as monotherapy for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection
Pharmaceutical company
MSD
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
13 May 2019